Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist

• Main Authors: Erik Rein‐Hedin (Author), Folke Sjöberg (Author), Cecilia Ganslandt (Author), Johan Skoog (Author), Helene Zachrisson (Author), Thomas Bengtsson (Author), Carl‐Johan Dalsgaard (Author)
• Format: Book
• Published: Wiley, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease. This phase I, open‐label, pharmacodynamic study investigated vascular effects of buloxibutid in five healthy male volunteers....